Molecular Templates Management
Management Kriterienprüfungen 0/4
Wichtige Informationen
Eric Poma
Geschäftsführender
US$857.8k
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 72.4% |
| Amtszeit als Geschäftsführer | 15.4yrs |
| Eigentum des Geschäftsführers | 0.3% |
| Durchschnittliche Amtszeit des Managements | less than a year |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 6.8yrs |
Jüngste Management Updates
Recent updates
Little Excitement Around Molecular Templates, Inc.'s (NASDAQ:MTEM) Revenues As Shares Take 48% Pounding
Apr 03
Lacklustre Performance Is Driving Molecular Templates, Inc.'s (NASDAQ:MTEM) 26% Price Drop
Dec 20There's No Escaping Molecular Templates, Inc.'s (NASDAQ:MTEM) Muted Revenues Despite A 45% Share Price Rise
Apr 17What Does The Future Hold For Molecular Templates, Inc. (NASDAQ:MTEM)? These Analysts Have Been Cutting Their Estimates
Nov 16Time To Worry? Analysts Are Downgrading Their Molecular Templates, Inc. (NASDAQ:MTEM) Outlook
Aug 14Molecular Templates GAAP EPS of -$0.44 misses by $0.01, revenue of $4.42M misses by $2.6M
Aug 11Rock star Growth Puts Molecular Templates (NASDAQ:MTEM) In A Position To Use Debt
Apr 29Health Check: How Prudently Does Molecular Templates (NASDAQ:MTEM) Use Debt?
Dec 30Some Analysts Just Cut Their Molecular Templates, Inc. (NASDAQ:MTEM) Estimates
Nov 25Is Molecular Templates (NASDAQ:MTEM) Using Debt In A Risky Way?
Sep 22News Flash: Analysts Just Made A Notable Upgrade To Their Molecular Templates, Inc. (NASDAQ:MTEM) Forecasts
Aug 15Need To Know: Analysts Just Made A Substantial Cut To Their Molecular Templates, Inc. (NASDAQ:MTEM) Estimates
May 18Brokers Are Upgrading Their Views On Molecular Templates, Inc. (NASDAQ:MTEM) With These New Forecasts
Mar 21Need To Know: The Consensus Just Cut Its Molecular Templates, Inc. (NASDAQ:MTEM) Estimates For 2021
Feb 21Is Molecular Templates (NASDAQ:MTEM) A Risky Investment?
Jan 26
Molecular Templates updates on study of MT5111, plans breast cancer expansion cohort in 1H21
Dec 22Here's What We Think About Molecular Templates' (NASDAQ:MTEM) CEO Pay
Dec 04Molecular Templates: Progress Stalled As Partial Hold Placed On Pivotal ETB Trial
Nov 17Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$18m |
| Dec 31 2023 | US$858k | US$621k | -US$8m |
| Sep 30 2023 | n/a | n/a | -US$26m |
| Jun 30 2023 | n/a | n/a | -US$47m |
| Mar 31 2023 | n/a | n/a | -US$60m |
| Dec 31 2022 | US$2m | US$600k | -US$93m |
| Sep 30 2022 | n/a | n/a | -US$81m |
| Jun 30 2022 | n/a | n/a | -US$87m |
| Mar 31 2022 | n/a | n/a | -US$78m |
| Dec 31 2021 | US$4m | US$577k | -US$83m |
| Sep 30 2021 | n/a | n/a | -US$101m |
| Jun 30 2021 | n/a | n/a | -US$94m |
| Mar 31 2021 | n/a | n/a | -US$110m |
| Dec 31 2020 | US$5m | US$560k | -US$105m |
| Sep 30 2020 | n/a | n/a | -US$92m |
| Jun 30 2020 | n/a | n/a | -US$107m |
| Mar 31 2020 | n/a | n/a | -US$85m |
| Dec 31 2019 | US$2m | US$515k | -US$69m |
| Sep 30 2019 | n/a | n/a | -US$60m |
| Jun 30 2019 | n/a | n/a | -US$27m |
| Mar 31 2019 | n/a | n/a | -US$28m |
| Dec 31 2018 | US$4m | US$500k | -US$30m |
| Sep 30 2018 | n/a | n/a | -US$31m |
| Jun 30 2018 | n/a | n/a | -US$36m |
| Mar 31 2018 | n/a | n/a | -US$31m |
| Dec 31 2017 | US$3m | US$448k | -US$24m |
Geschäftsführer
Eric Poma (52 yo)
15.4yrs
Amtszeit
US$857,769
Vergütung
Dr. Eric E. Poma, Ph D., is the Chief Executive Officer and Chief Scientific Officer of Molecular Templates, Inc. since 2009 and served as its President. Dr. Poma founded Private Molecular in February 2009...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO, Chief Scientific Officer & Director | 15.4yrs | US$857.77k | 0.28% $ 24.2k | |
| President | 1.4yrs | US$579.24k | 0.097% $ 8.3k | |
| Chief Operating Officer | less than a year | keine Daten | keine Daten | |
| Chief Strategy Officer & Head of IR | less than a year | keine Daten | keine Daten | |
| Senior Vice President & General Counsel | less than a year | keine Daten | keine Daten | |
| Senior VP & Head of CMC Development | no data | keine Daten | keine Daten | |
| Senior VP and Head of Preclinical Development & Translational Medicine | less than a year | keine Daten | keine Daten |
0.8yrs
Durchschnittliche Betriebszugehörigkeit
52yo
Durchschnittliches Alter
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO, Chief Scientific Officer & Director | 6.8yrs | US$857.77k | 0.28% $ 24.2k | |
| Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
| Independent Director | 6.8yrs | US$59.29k | 0% $ 0 | |
| Independent Chairman | 6.8yrs | US$87.29k | 0.041% $ 3.5k | |
| Independent Director | 6.8yrs | US$54.29k | 0% $ 0 | |
| Independent Director | 4.5yrs | US$49.29k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
| Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
| Director | 2.3yrs | US$561.35k | 0% $ 0 |
6.8yrs
Durchschnittliche Betriebszugehörigkeit
67yo